Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the cancer and prevent recurrence after surgery. Treatment given before surgery is called neoadjuvant therapy. The purpose of this study is to find out whether neoadjuvant therapy with nivolumab and ipilimumab can kill melanoma tumors before surgery and prevent disease from coming back after surgery. This study also explores a new, experimental PET scan that images the immune system to see if it is related to treatment outcomes.
Sponsor:
Memorial Sloan Kettering Cancer Center
Phase:
Phase 2
Contacts:
Michael Postow, MD (Principal Investigator)postowm@mskcc.org
646-888-4589
Neeta Pandit-Taskarpandit-n@mskcc.org
2126393046
Government Study Link:
NCT05289193 - Click here to see study onClinicalTrials.gov
Help us improve your experience